Literature DB >> 17221002

Phobias, other psychiatric comorbidities and chronic migraine.

Felipe Corchs1, Juliane P P Mercante, Vera Z Guendler, Domingos S Vieira, Marcelo R Masruha, Frederico R Moreira, Marcio Bernik, Eliova Zukerman, Mario F P Peres.   

Abstract

BACKGROUND: Comorbidity of chronic migraine (CM) with psychiatric disorders, mostly anxiety and mood disorders, is a well-recognized phenomenon. Phobias are one of the most common anxiety disorders in the general population. Phobias are more common in migraineurs than non-migraineurs. The clinical profile of phobias in CM has never been studied.
METHOD: We investigated the psychiatric profile in 56 patients with CM using the SCID I/P interview.
RESULTS: Lifetime criteria for at least one mental disorder was found in 87.5% of the sample; 75% met criteria for at least one lifetime anxiety disorder and 60.7% of our sample fulfilled DSM-IV criteria for lifetime phobic avoidant disorders. Mood and anxiety scores were higher in phobic patients than in non-phobic CM controls. Number of phobias correlated with higher levels of anxiety and depression.
CONCLUSION: Phobias are common in CM. Its recognition may influence its management. Early treatment may lead to better prognosis.

Entities:  

Mesh:

Year:  2006        PMID: 17221002     DOI: 10.1590/s0004-282x2006000600012

Source DB:  PubMed          Journal:  Arq Neuropsiquiatr        ISSN: 0004-282X            Impact factor:   1.420


  8 in total

1.  Vestibular migraine patients are more anxious than migraine patients without vestibular symptoms.

Authors:  Özge Kutay; Gülden Akdal; Pembe Keskinoğlu; Birgül Dönmez Balcı; Tunç Alkın
Journal:  J Neurol       Date:  2017-03-09       Impact factor: 4.849

2.  Determinants of depression and anxiety in family practice patients with comorbidities.

Authors:  Zalika Klemenc-Ketis; Janko Kersnik; Darinka Novak-Glavac
Journal:  Wien Klin Wochenschr       Date:  2010-05       Impact factor: 1.704

3.  Anxiety disorders in headache patients in a specialised clinic: prevalence and symptoms in comparison to patients in a general neurological clinic.

Authors:  D Mehlsteibl; C Schankin; P Hering; P Sostak; A Straube
Journal:  J Headache Pain       Date:  2011-02-06       Impact factor: 7.277

4.  Cerebral gray matter volume in patients with chronic migraine: correlations with clinical features.

Authors:  Gianluca Coppola; Barbara Petolicchio; Antonio Di Renzo; Emanuele Tinelli; Cherubino Di Lorenzo; Vincenzo Parisi; Mariano Serrao; Valentina Calistri; Stefano Tardioli; Gaia Cartocci; Anna Ambrosini; Francesca Caramia; Vittorio Di Piero; Francesco Pierelli
Journal:  J Headache Pain       Date:  2017-12-08       Impact factor: 7.277

5.  Understanding the nature of psychiatric comorbidity in migraine: a systematic review focused on interactions and treatment implications.

Authors:  Thomas Dresler; Salvatore Caratozzolo; Kaat Guldolf; Jana-Isabel Huhn; Carmela Loiacono; Triinu Niiberg-Pikksööt; Marta Puma; Giorgia Sforza; Anna Tobia; Raffaele Ornello; Gianluca Serafini
Journal:  J Headache Pain       Date:  2019-05-09       Impact factor: 7.277

Review 6.  Comorbidities of primary headache disorders: a literature review with meta-analysis.

Authors:  Valeria Caponnetto; Manuela Deodato; Paolo Martelletti; Alberto Raggi; Micaela Robotti; Maria Koutsokera; Valeria Pozzilli; Cristina Galati; Giovanna Nocera; Eleonora De Matteis; Gioacchino De Vanna; Emanuela Fellini; Gleni Halili; Daniele Martinelli; Gabriele Nalli; Serena Serratore; Irene Tramacere
Journal:  J Headache Pain       Date:  2021-07-14       Impact factor: 7.277

7.  Cephalalgiaphobia as a feature of high-frequency migraine: a pilot study.

Authors:  Giulia Giannini; Stefano Zanigni; Daniela Grimaldi; Roberto Melotti; Giulia Pierangeli; Pietro Cortelli; Sabina Cevoli
Journal:  J Headache Pain       Date:  2013-06-10       Impact factor: 7.277

8.  The development and initial tests for the psychometric properties of the COVID-19 Phobia Scale (C19P-S).

Authors:  Ibrahim Arpaci; Kasım Karataş; Mustafa Baloğlu
Journal:  Pers Individ Dif       Date:  2020-05-11
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.